Steve Tullman's career in life sciences spans more than 30 years and includes numerous Chairman, CEO, and founding credits, with the creation of ten biotechnology companies. He currently serves as the Managing Member of Nexstone Innovation, Executive Chairman of Nexstone Immunology and Chairman of NexEos Bio. Steve co-founded NeXeption, Inc. in 2011 and NeXeption, LLC in 2012 to focus on building biotech organizations designed to identify and advance programs with significant unmet medical needs. His previous Chairmanships include serving Onspira Therapeutics, Inc. until its acquisition by Altavant Sciences/Sumitomo Dainippon Pharma in 2019, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), Ralexar Therapeutics, Inc., and Vicept Therapeutics, Inc. until its acquisition by Allergan, Inc. He also served as Chairman, President and CEO of Ceptaris Therapeutics, Inc. until its acquisition by Actelion in 2013. He created Ception Therapeutics, Inc. in 2005 and served as its President and CEO until its acquisition by Cephalon, Inc. in 2010.
Kelly Copeland was a founding partner of NeXeption and served on the founding management team for NexEos Bio. She currently serves as the Senior Vice President of Operations and Product Strategy for Nexstone Immunology.
Kelly brings more than 20 years in the development of pharmaceutical products to Nexstone. She has served in strategic roles within GlaxoSmithKline (GSK) where she provided commercial strategy and product development support to programs from pre-clinical states of development through global registration. She has worked across a number of therapeutic areas including respiratory and inflammation, has served as the commercial head for the Center for Excellence in External Drug Discovery (CEEDD). Kelly has been a founding member of a number of successful development stage biotechnology companies including Ception Therapeutics, Ceptaris Therapeutics and Onspira Therapeutics, which were all focused on rare diseases.
Brian Lortie is an experienced business leader with a record of accomplishment across a full range of commercial, strategic, operational, and development responsibilities developed during a career spanning over 25 years of global experience in emerging, mid-size and large organizations.
Brian is President and CEO at Nexstone Immunology, where he is responsible for executive leadership of this clinical-stage biopharmaceutical company focused on developing novel therapies for immunologic and inflammatory diseases. Prior to Nexstone Immunology, he was President and CEO at Onspira Therapeutics which was sold to Altavant Sciences/Sumitomo Dainippon Pharma in 2019.
Prior to this, Brian served as President, Branded Pharmaceuticals at Endo Pharmaceuticals, where he was responsible for the leadership of a $2 billion business focused on the areas of pain therapeutics, urology, orthopedics, and endocrinology. Under his leadership, the Endo Pharmaceuticals business experienced significant growth through successful progression of pipeline assets and M&A activities.
Brian began his pharmaceutical career at SmithKline Beecham / GlaxoSmithKline, where he progressed through leadership roles including General Manager-Ireland, Vice-President of the Diabetes, Urology and Anti-Infective Business Group, Vice-President and Global Head of HPV Vaccine Development, and Vice-President, Venture and Business Development.
Brian holds a Bachelor of Arts degree with honors in Biology and Psychology from Boston University and studied at the Villanova University Graduate School of Business.
Copyright © 2022 Nexstone Innovation LLC - All Rights Reserved.